-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 TGzhhVDnEKen63c9YTgzOa17fi6nVwOGOEnsaEvG0slK7vX/2qGZf7sFkT6Ey+I4
 uxakBydrK2kjtDyqbtNwwA==

<SEC-DOCUMENT>0001275287-07-001840.txt : 20070418
<SEC-HEADER>0001275287-07-001840.hdr.sgml : 20070418
<ACCEPTANCE-DATETIME>20070418160222
ACCESSION NUMBER:		0001275287-07-001840
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070409
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070418
DATE AS OF CHANGE:		20070418

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TRANSGENOMIC INC
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30975
		FILM NUMBER:		07773535

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		4027385480

	MAIL ADDRESS:	
		STREET 1:		12325 EMMET STREET
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ti9650.txt
<DESCRIPTION>FORM 8-K
<TEXT>
================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

                Date of Report (Date of earliest event reported):
                                  April 9, 2007

                               TRANSGENOMIC, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

            Delaware                   000-30975                911789357
         --------------               ------------       ----------------------
           (State of                  (Commission             (IRS Employer
         Incorporation)               File Number)       Identification Number)

         12325 Emmet Street, Omaha, Nebraska                     68164
       ----------------------------------------               ----------
       (Address of principal executive offices)               (Zip Code)

                                 (402) 452-5400
              ----------------------------------------------------
              (Registrant's telephone number, including area code)

                                 Not applicable
          -------------------------------------------------------------
          (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities
     Act (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange
     Act (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

================================================================================

<PAGE>

ITEM 5.02   ELECTION OF DIRECTOR.

        On April 9, 2007, the Registrant's Board of Directors appointed
Frank R. Witney to serve as a Class I Director. Dr. Witney has not been
appointed to any committees of the Board of Directors at this time. There are no
family relationships between Dr. Witney and any other director or executive
officer of the Registrant and he was not selected by the Board of Directors to
serve as a Director pursuant to any arrangement or understanding with any
person. Dr. Witney has not engaged in any transaction with the Registrant that
would be reportable as a related party transaction under the rules of the SEC.

ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS.

     99.1   Press Release, dated April 18, 2007, announcing the appointment
of Frank R. Witney to the Registrant's Board of Directors.

<PAGE>

                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

Dated:  April 18, 2007                               TRANSGENOMIC, INC.


                                                     By: /s/ Debra A. Schneider
                                                         -----------------------
                                                         Debra A. Schneider
                                                         Chief Financial Officer
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ti9650ex991.txt
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
                                                                    Exhibit 99.1

          TRANSGENOMIC, INC. ANNOUNCES APPOINTMENT OF NEW BOARD MEMBER

    OMAHA, Neb., April 18 /PRNewswire-FirstCall/ -- Transgenomic, Inc.
(OTC Bulletin Board: TBIO) announced that it has appointed Frank R. Witney,
Ph.D., to its Board of Directors.  Dr. Witney is currently President, CEO and
a member of the Board of Directors of Panomics Inc.  Panomics develops and
markets products for single and multiplex gene and protein expression analysis
from cell and tissue specimens, as well as cell-based assays.  Dr. Witney is
currently serving as a board member for Applied Precision, a privately held
company that serves the semiconductor process and measurement systems and life
science imaging market.  Dr. Witney's professional and academic interests have
been focused on the biotech and life sciences market throughout his career.
Prior to his current position, he was President of PerkinElmer's Drug
Discovery Business Unit and before that he served as President and COO of
Packard BioSciences.

    In making this announcement, Transgenomic President and CEO, Craig Tuttle,
stated, "We are very excited to have Dr. Witney join the Company's Board of
Directors.  Dr. Witney has a tremendous reputation in the life sciences
marketplace and as a successful biotech entrepreneur.  He brings a detailed
understanding of genomics and gene regulation for drug targeting and
therapeutic research to our Board.  He will provide significant leadership to
the Company as we expand our own genetic testing services laboratory business
in the cancer discovery area."  Mr. Tuttle further noted, "We are entering an
exciting time at Transgenomic where we are applying our many years of mutation
discovery and technical expertise to expand our product and service offerings
and drive the company's growth.  Adding Dr. Witney to the Board will aid us
significantly in achieving these goals."

    About Transgenomic:  A decade of discovery 1997 - 2007

    Transgenomic is a global biotechnology company that provides unique
products and services for automated high sensitivity genetic variation and
mutation analysis.  Their offerings include systems, products, discovery and
laboratory testing services to the academic and medical research, clinical
laboratory and pharmaceutical markets in the fields of pharmacogenomics and
personalized medicine.  Specific offerings include WAVE(R) DHPLC Systems,
related consumables and assay kits, cytogenetics automated systems, and
Transgenomic Discovery and CLIA Lab Services.  Transgenomic Discovery and Lab
Services utilize their technology and expertise to provide a menu of mutation
scanning tests for over 700 cancer-associated genes and more than 60 validated
diagnostic tests to meet the needs of pharmaceutical and biotech companies,
research and clinical laboratories, physicians and patients.  For more
information about the innovative systems, products and services offered by
Transgenomic, please visit:  www.transgenomic.com.

    Transgenomic Cautionary Statements

    Certain statements in this press release constitute "forward-looking
statements" of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause our actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements.  Forward-looking statements include,
but are not limited to, those with respect to management's current views and
estimates of future economic circumstances, industry conditions, company
performance and financial results, including the ability of the Company to
grow its involvement in the diagnostic products and services markets.  The
known risks, uncertainties and other factors affecting these forward-looking
statements are described from time to time in Transgenomic's reports to the
Securities and Exchange Commission.  Any change in such factors, risks and
uncertainties may cause the actual results, events and performance to differ
materially from those referred to in such statements.  Accordingly, the
company claims the protection of the safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform Act of 1995
with respect to all statements contained in this press release.  All
information in this press release is as of the date of the release and
Transgenomic does not undertake any duty to update this information, including
any forward-looking statements, unless required by law.

SOURCE  Transgenomic, Inc.
    -0-                             04/18/2007
    /CONTACT:  Debra Schneider, Chief Financial Officer of Transgenomic, Inc.,
+1-402-452-5400, or fax, +1-402-452-5461, investorrelations@transgenomic.com/
    /Web site:  http://www.transgenomic.com /
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
